Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Sep 27, 2022; 14(9): 950-962
Published online Sep 27, 2022. doi: 10.4240/wjgs.v14.i9.950
Table 1 Clinical and pathological characteristics of laparoscopic assisted gastrectomy and totally laparoscopic gastrectomy group for elderly patients (mean ± SD)
Characteristics
LAG group (n = 232)
TLG group (n = 230)
P value
Gender0.472
Male183175
Female4955
Age (yr)74.62 ± 3.8074.69 ± 4.100.848
BMI (kg/m2)23.31 ± 3.0823.64 ± 3.460.285
aCCI score, n (%)0.608
0-4188182
> 44448
ASA score, n (%)0.426
I11
II177168
III5461
History of abdominal surgery0.232
No189177
Yes4353
Tumor resection0.163
Distal125109
Total107121
Neoadjuvant chemotherapy0.201
No223215
Yes915
Tumor diameters (cm) (median, IQR)4.00 (2.58-6.00)4.00 (2.65-5.5)0.230
pT0.895
T020
T13843
T23637
T3116107
T44043
pN0.544
N08377
N13333
N24948
N36772
pTNM0.857
020
I5260
II6557
III113113
Nerve invasion0.249
Yes7182
No161148
Vascular invasion0.685
Yes9186
No141144
Differentiation 0.945
Well/moderate151149
Poor/undifferentiated8181
Table 2 Perioperative outcomes between laparoscopic assisted gastrectomy and totally laparoscopic gastrectomy group for elderly patients (mean ± SD)
Variable
LAG group (n = 232)
TLG group (n = 230)
P value
Surgical time, min221.34 ± 54.96216.48 ± 52.530.332
Blood loss, ml (median, IQR)100.0 (50.0-200.0)100.0 (50.0-100.0)0.000
Anastomotic approach
B11714
B2 (+Braun)3936
Roux-en-Y176180
Retrieved lymph nodes, n29.32 ± 11.2730.69 ± 12.650.218
Extent of resection
R0218215
R1/R21415
Time to first flatus, d4.43 ± 1.203.79 ± 1.150.000
Postoperative day, d (median, IQR)8.0 (7.0-10.0)7.75 (6.0-9.0)0.000
Total complication rate (%)61 (26.3)38 (16.5)0.010
Anastomotic-related complication rate (%)8 (3.4)6 (2.6)0.599
Clavien-Dindo classification
Grade II
Deep venous thrombosis11
Lymphatic leakage10
Gastroplegia12
Anaphylaxis11
Ileus01
Cardiac failure10
Hypoproteinemia107
Anemia127
Cholecystitis20
Incision infection21
Atrial fibrillation42
Pneumonia82
Anastomotic leakage52
Anastomotic bleeding02
Anastomotic stenosis10
Duodenal trump leakage21
Grade IIIa
Deep venous thrombosis00
Pleural effusion43
Anastomotic leakage22
Duodenal trump leakage11
Abdominal bleeding01
Grade IV
Cardiac failure20
Abdominal bleeding11
Acute cerebral infarction01
Severe complication rate (%)10 (4.3)9 (3.9)0.830
Table 3 Uni- and multivariate analysis of postoperative complications for elderly patients
FactorUnivariate analysis
P valueMultivariate analysis
P value
OR
95%CI
OR
95%CI
Sex0.462
Male1.000
Female1.2150.724-2.038
Age (yr)0.0270.157
< 751.0001.000
≥ 751.6551.058-2.5871.4220.874-2.313
BMI (kg/m2)0.321
< 251.000
≥ 250.7790.475-1.276
Surgical approach0.0110.011
LAG1.0001.000
TLG0.5550.352-0.8740.5390.335-0.865
aCCI score0.0740.416
0-41.0001.000
> 41.6030.952-2.6991.2760.709-2.294
ASA score0.0300.069
≤ II1.0001.000
> II1.7131.055-2.7831.6260.963-2.744
Tumor resection0.846
Distal1.000
Total0.9570.613-1.493
Neoadjuvant chemotherapy0.752
No1.000
Yes1.1650.452-3.000
pTNM stage0.918
0-I1.000
II1.0720.571-2.012
III1.1240.645-1.958
Tumor diameter (cm)0.0200.116
≤ 31.0001.000
> 31.8151.101-2.9951.5350.900-2.618
Operation time (min)0.0310.039
≤ 2201.0001.000
> 2201.6361.047-2.5581.6711.027-2.718
Estimated blood loss (mL)0.1200.895
≤ 2001.0001.000
> 2001.6280.880-3.0121.0470.530-2.070
Vascular invasion0.0350.223
No1.0001.000
Yes1.6201.034-2.5381.3490.834-2.185
Nerve invasion0.667
No1.000
Yes0.9010.559-1.451
Differentiation0.760
Well/moderate1.000
Poor/undifferentiated1.0750.676-1.708
R0 resection 0.1970.263
No1.0001.000
Yes1.7150.755-3.8951.6390.690-3.892
Table 4 Quality of life using European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire and STO-22 questionnaire between laparoscopic assisted gastrectomy and totally laparoscopic gastrectomy group
FactorBaseline
P valuePostoperative 3 mo
P value
LAG group
TLG group
LAG group
TLG group
QLQ-C30 questionnaire
Global status91.6 (91.6-100)91.6 (91.6-100)0.09691.6 (91.6-100)91.6 (91.6-100)0.934
Physical functioning100 (93.3-100)100 (93.3-100)0.863100 (93.3-100)96.7(93.3-100)0.777
Role functioning100 (83.3-100)100 (83.3-100)0.269100 (83.3-100)83.3 (83.3-100)0.804
Emotional functioning91.6 (91.6-100)91.6 (91.6-100)0.34391.6 (91.6-100)91.6 (91.6-100)0.880
Cognitive functioning100 (83.3-100)100 (83.3-100)0.962100 (83.3-100)100 (83.3-100)0.925
Social functioning100 (83.3-100)100 (83.3-100)0.853100 (83.3-100)100 (83.3-100)0.925
Fatigue0 (0-0)0 (0-0)0.4710 (0-0)0 (0-11)0.170
Nausea and vomiting0 (0-0)0 (0-0)0.1330 (0-12.5)0 (0-0)0.043
Pain0 (0-0)0 (0-0)0.5070 (0-0)0 (0-0)0.772
Dyspnea0 (0-0)0 (0-0)0.1650 (0-0)0 (0-0)0.880
Insomnia0 (0-33.3)0 (0-33.3)0.4280 (0-33.3)0 (0-33.3)0.984
Appetite loss0 (0-0)0 (0-33.3)0.4940 (0-33.3)0 (0-33.3)0.899
Constipation0 (0-33.3)0 (0-33.3)0.52933.3 (0-33.3)0 (0-33.3)0.024
Diarrhea0 (0-0)0 (0-0)0.1220 (0-0)0 (0-0)0.705
Financial difficulties0 (0-33.3)0 (0-33.3)0.0810 (0-33.3)0 (0-33.3)0.355
STO-22 questionnaire
Dysphagia0 (0-0)0 (0-0)0.5470 (0-22)0 (0-11)0.169
Pain0 (0-0)0 (0-0)0.7930 (0-14.6)0 (0-8.3)0.389
Reflux0 (0-11)0 (0-11)0.4440 (0-22)0 (0-22)0.548
Eating restrictions0 (0-0)0 (0-0)0.4410 (0-8.3)0 (0-8.3)0.848
Anxiety0 (0-11)0 (0-11)0.9520 (0-22)0 (0-22)0.214
Dry mouth0 (0-0)0 (0-0)0.6810 (0-0)0 (0-0)0.982
Taste0 (0-0)0 (0-0)0.6090 (0-0)0 (0-0)0.858
Body image0 (0-0)0 (0-0)0.5730 (0-33.3)0 (0-0)0.000
Hair loss0 (0-0)0 (0-0)0.4420 (0-0)0 (0-0)0.077